UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 1528, 2010

SYMBOLLON PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware	0-22872	36-3463683
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

99 West Street, Suite J, Medfield, Massachusetts 02052

(Address of principal executive offices) (Zip Code)

(508) 242-7500

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13-4(c))

Item 34.0201 ~~Unregistered~~Changes ~~Sales~~in ofRegistrant’s ~~Equity~~Certifying ~~Securities~~Accountant.

~~Item~~On 5July 21, 2010, Symbollon Pharmaceuticals, Inc.02 ~~Departure~~(the of“Company”) ~~Directors~~was ornotified ~~Certain~~that ~~Officers;~~effective ~~Election~~July 20, 2010, McGladrey & Pullen, LLP (“McGladrey”) acquired certain assets of ~~Directors;~~Caturano ~~Appointment~~and Company, Inc. (formerly Caturano and Company, P.C.), the Company’s independent registered public accounting firm (“Caturano”), and substantially all of ~~Certain~~the ~~Officers;~~officers ~~Compensatory~~and ~~Arrangements~~employees of ~~Certain~~Caturano ~~Officers~~joined McGladrey. As a result, on October 28, 2010, Caturano resigned as the independent registered public accounting firm for the Company. The Company is currently evaluating plans for the successor auditor.

OnThe ~~October~~audit ~~15,~~report ~~2010,~~of Caturano on the ~~Company’s~~financial ~~Board~~statements of ~~Directors~~the ~~expanded~~Company for the ~~Board~~period ending December 31, 2009 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified to ~~eight~~the ~~members~~uncertainty, byaudit ~~appointing~~scope ~~three~~or ~~new~~accounting ~~directors. The~~principles, ~~new~~except ~~directors~~that ~~are:~~it did contain an explanatory paragraph disclosing the uncertainty regarding the ability of the Company to continue as a going concern.

~~Kelly~~During ~~Black-White~~the most recent fiscal period ended December 31, 502009 –and ~~Ms.~~through ~~Black-White~~October is28, 2010 there were: (1) no disagreements between the ~~president~~Company and Caturano on any matter of ~~Premier~~accounting ~~Funding~~principles ~~Services~~or practices, ~~Inc.~~financial ~~and~~statement ~~Premier~~disclosure, ~~Media~~or ~~Services~~auditing scope or procedures, ~~Inc. She~~which ~~specializes~~disagreements, inif ~~providing~~not ~~investor~~resolved ~~and~~to ~~public~~the ~~relations~~satisfaction ~~services~~of Caturano would have caused them to ~~small~~make ~~cap~~reference ~~market~~thereto ~~companies~~in their reports on the Company’s financial statements for such years, ~~including~~and ~~Symbollon~~(2) no reportable events within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

~~Yongjun~~The ~~Duan,~~Company 52has –provided ~~Dr.~~Caturano ~~Duan~~a iscopy of the ~~founder~~disclosures ~~and~~in ~~Chairman~~this ofForm ~~the~~8-K ~~Board~~and ofhas ~~Xi’an~~requested ~~Maidelfa~~that ~~Pharmaceutical~~Caturano ~~Co.,~~furnish ~~Ltd.,~~it with a ~~fully-integrated~~letter ~~pharmaceutical~~addressed ~~company~~to ~~currently~~the ~~marketing~~Securities ~~products~~and toExchange ~~the~~Commission ~~dairy~~stating ~~and~~whether ~~aquaculture~~or ~~markets~~not it agrees with the Company’s statements in ~~China~~this Item 4. Dr01(a). A ~~Duan~~copy ~~previously~~of ~~served~~the asletter ~~the~~dated ~~director~~October of28, ~~research~~2010 ~~and~~is ~~development~~filed ofas ~~Symbollon~~Exhibit 16.1 to this Form 8-K.

~~Timothy~~Item ~~Kane, 49 – Mr~~9. ~~Kane is the Chief Operating Officer of McSweeney & Ricci Insurance Agency, Inc~~01., Financial ~~the~~Statements ~~14th~~and ~~largest independent insurance brokerage agency in Massachusetts. McSweeney & Ricci has provided Symbollon insurance brokerage services.~~Exhibits

~~The Company granted each of the new director 500,000 shares of Class A common stock~~(d) Exhibits. The shares will vest one-half each of the next two anniversaries of the grant date. Each director will also participate in the Company’s nonemployee director stock option plan which will provide each director annually with an option to purchase 10,000 shares of the Company’s common stock.

16.1

Letter from Caturano and Company, Inc. dated October 28, 2010.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 2128, 2010

SYMBOLLON PHARMACEUTICALS, INC.

By: /s/ Paul C. Desjourdy

Paul C. Desjourdy

President, Chief Executive Officer and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No.	Description	Page No.
16.1	Letter from Caturano and Company, Inc. dated October 28, 2010.

E-1

Filing Compare · SYMBOLLON CORP